DGAP-News

MOLOGEN AG: First patient enrolled in TEACH study to treat HIV patients with MGN1703

DGAP-News: MOLOGEN AG / Key word(s): Study
MOLOGEN AG: First patient enrolled in TEACH study to treat HIV
patients with MGN1703

03.06.2015 / 10:00

---------------------------------------------------------------------

MOLOGEN AG: First patient enrolled in TEACH study to treat HIV patients
with MGN1703

Berlin, June 3, 2015 - The biotechnology company MOLOGEN AG announced today
that its partner, the Danish Aarhus University Hospital, treated the first
patients in the TEACH study. The collaboration started in early May 2015.
Patient enrollment is expected to be completed within the next months.

The aim of the so-called TEACH study is to see if the immunotherapy with
MGN1703 can activate the innate and adaptive immune system in HIV (Human
Immunodeficiency Virus) patients to enhance killing of the HIV infected
cells. Aarhus University Hospital will conduct the trial in two hospital
centers in Denmark and already received respective funding from the
American Foundation for AIDS research (amfAR). MOLOGEN will provide the
immunomodulator MGN1703. This is the first time that MGN1703 is evaluated
in patients with diseases other than cancer. Thus the potential range of
applications of the product could be expanded.

MGN1703 is currently being investigated in the registration trial IMPALA in
colorectal cancer and in the randomized trial IMPULSE in small cell lung
cancer. Both studies are currently enrolling patients.

About TEACH
TEACH (Toll-like receptor 9 enhancement of antiviral immunity in chronic
HIV infection) is a non-randomized interventional phase I/IIa trial of
MGN1703 in HIV-infected patients. Participants will receive four weeks of
MGN1703 therapy (60 mg s.c. twice weekly). During these four weeks, each
participant will be closely monitored for the safety and therapeutic
effects of the drug. 14-16 patients will participate in two study centers
in Denmark.

The primary endpoint of the study is the change in proportions of activated
natural killer cells in the patients. Secondary study endpoints include,
among others, a collection of safety, virological, immunological and
pharmacodynamic data.

HIV infects the immune system and destroys or affects the proper function
of immune cells. Without antiretroviral treatment this eventually leads to
immune deficiency and the immune system can no longer fight off a wide